Tower Research Capital LLC (Trc) Alnylam Pharmaceuticals, Inc. Transaction History

Tower Research Capital LLC (Trc)

$3.53 Billion
Q2 2025

A detailed history of Tower Research Capital LLC (Trc) transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 64 shares of ALNY stock, worth $29,503. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 1,383 95.37%

Holding current value

$29,503

Previous $373,000 94.64%

% of portfolio

0.0%

Previous 0.01%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$224.32 - $326.09 $295,878 - $430,112	-1,319 Reduced 95.37%	64 $20,000
Q1 2025 May 15, 2025	SELL	$233.07 - $290.7 $931,813 - $1.16 Million	-3,998 Reduced 74.3%	1,383 $373,000
Q4 2024 Feb 13, 2025	BUY	$232.27 - $300.43 $1.12 Million - $1.45 Million	4,840 Added 894.64%	5,381 $1.27 Million
Q3 2024 Nov 14, 2024	SELL	$233.81 - $287.01 $101,005 - $123,988	-432 Reduced 44.4%	541 $148,000
Q2 2024 Aug 13, 2024	SELL	$143.31 - $247.0 $109,202 - $188,214	-762 Reduced 43.92%	973 $236,000
Q1 2024 May 15, 2024	SELL	$146.51 - $198.2 $723,319 - $978,513	-4,937 Reduced 74.0%	1,735 $259,000
Q4 2023 Feb 13, 2024	BUY	$151.41 - $196.57 $239,530 - $310,973	1,582 Added 31.08%	6,672 $1.28 Million
Q3 2023 Nov 14, 2023	SELL	$170.77 - $211.65 $765,220 - $948,403	-4,481 Reduced 46.82%	5,090 $901,000
Q2 2023 Aug 14, 2023	BUY	$185.01 - $212.05 $1.65 Million - $1.89 Million	8,895 Added 1315.83%	9,571 $1.82 Million
Q1 2023 May 09, 2023	SELL	$182.66 - $235.53 $113,249 - $146,028	-620 Reduced 47.84%	676 $135,000
Q4 2022 Feb 10, 2023	SELL	$185.53 - $241.31 $291,838 - $379,580	-1,573 Reduced 54.83%	1,296 $308,000
Q3 2022 Nov 10, 2022	SELL	$138.54 - $232.0 $1.5 Million - $2.51 Million	-10,801 Reduced 79.01%	2,869 $575,000
Q2 2022 Aug 15, 2022	SELL	$120.42 - $169.29 $55,995 - $78,719	-465 Reduced 3.29%	13,670 $1.99 Million
Q1 2022 May 12, 2022	BUY	$127.18 - $173.91 $941,640 - $1.29 Million	7,404 Added 110.0%	14,135 $2.31 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $931,032 - $1.22 Million	5,835 Added 651.23%	6,731 $1.14 Million
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $200,644 - $245,536	-1,182 Reduced 56.88%	896 $169,000
Q2 2021 Aug 16, 2021	BUY	$128.63 - $176.89 $102,003 - $140,273	793 Added 61.71%	2,078 $352,000
Q1 2021 May 17, 2021	SELL	$126.83 - $175.69 $877,283 - $1.22 Million	-6,917 Reduced 84.33%	1,285 $181,000
Q4 2020 Feb 16, 2021	BUY	$122.97 - $147.0 $476,385 - $569,478	3,874 Added 89.51%	8,202 $1.07 Million
Q3 2020 Nov 16, 2020	BUY	$121.19 - $165.49 $350,360 - $478,431	2,891 Added 201.18%	4,328 $631,000
Q2 2020 Aug 13, 2020	BUY	$104.21 - $156.44 $147,144 - $220,893	1,412 Added 5648.0%	1,437 $213,000
Q1 2020 May 15, 2020	SELL	$93.12 - $133.99 $143,870 - $207,014	-1,545 Reduced 98.41%	25 $3,000
Q4 2019 Feb 07, 2020	BUY	$74.51 - $124.23 $116,980 - $195,041	1,570 New	1,570 $181,000
Q3 2019 Nov 05, 2019	SELL	$70.9 - $87.82 $58,705 - $72,714	-828 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$65.86 - $92.79 $44,521 - $62,726	676 Added 444.74%	828 $60,000
Q1 2019 May 14, 2019	BUY	$72.76 - $93.45 $11,059 - $14,204	152 New	152 $14,000
Q4 2018 Feb 14, 2019	SELL	$62.67 - $88.33 $81,094 - $114,299	-1,294 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$87.52 - $122.67 $100,210 - $140,457	1,145 Added 768.46%	1,294 $113,000
Q2 2018 Aug 15, 2018	SELL	$88.31 - $107.8 $478,640 - $584,276	-5,420 Reduced 97.32%	149 $15,000
Q1 2018 May 15, 2018	BUY	$115.92 - $148.54 $645,558 - $827,219	5,569 New	5,569 $663,000

Others Institutions Holding ALNY

# of Institutions

742

Shares Held

115M

Call Options Held

584K

Put Options Held

672K

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $56.7B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Account

Tower Research Capital LLC (Trc) Alnylam Pharmaceuticals, Inc. Transaction History